Loading…
Trial terminated
| why_stopped | null | → | The combination therapy arm of the study with pembrolizumab did not yield an efficacy signal, so enrollment into the combination therapy arm was terminated. The monotherapy arm of the study was fully enrolled and completed. |
| overall_status | Completed | → | Terminated |
Seven dimensions, unsigned magnitude 0–100. Direction is resolved separately, per entity, because one event is good for one name and bad for another.
No other named entities identified.This event has no scored competitor read-through.
No real valuation-relevant phase transition on a resolved asset for this event.This section fires only when the event carries a resolved asset and a real phase change — not guessed for every event.